Zobrazeno 1 - 10
of 333
pro vyhledávání: '"F, Wisløff"'
Autor:
H. C. Godal, F. Wisløff
Publikováno v:
Scandinavian Journal of Haematology. 27:45-50
100 patients with a modified Ivy bleeding time longer than 10 min in the presence of more than 80 x 10(9)/l blood platelets were studied retrospectively. 72 patients had repeated bleeding times between 10 and 20 min or one or more measurements exceed
Autor:
P. Andersen, T. R. Andersson, F. Wisløff, K. Løvåsen, C. Eika, B. Riis Strøm, G. E. Tjønnfjord, K. Fjæstad, E. Brandt, Bernt Ly
Publikováno v:
European Journal of Haematology. 47:333-337
All patients in the region with newly discovered M components were registered from 15 Aug. 1984-31 Dec. 1986. Among a total of 393 patients enrolled, 162 had multiple myeloma (MM). The incidence rate was 6.6 per 100,000 population per year (age-adjus
Publikováno v:
Thrombosis and Haemostasis. 83:704-708
SummaryThe Lupus Ratio (LR) test for lupus anticoagulants integrates screening, mixing with normal plasma and confirmation procedures into one assay. The sensitivity and reproducibility of the APTT based version of this assay was tested in an interla
Autor:
H.C. Godal, F. Wisløff
Publikováno v:
Scandinavian Journal of Haematology. 31:19-21
A case of previously undiagnosed congenital spherocytosis that became manifest during lymph node tubercolosis is described. It is suggested that mild forms of congenital spherocytosis are common, but may pass unnoticed unless revealed by an intercurr
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
F, Wisløff, J M, Tangen, L, Brinch, I M, Dahl, F X, Gruber, J, Hammerstrøm, A, Waage, I, Nesthus, P, Ernst
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 121(20)
Since the introduction of the simple cyclic oral treatment with melphalan and prednisone in the late 1960s, there has been no substantial improvement in the therapy of multiple myeloma. In 1994, the Nordic Myeloma Study Group initiated a population-b
Autor:
F, Wisløff
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 121(12)
Publikováno v:
European journal of haematology. 66(5)
We evaluated the costs and the cost utility of high-dose melphalan and autologous stem cell support followed by interferon maintenance relative to conventional treatment with melphalan and prednisone, in patients less than 60 yr of age with multiple
Autor:
F, Wisløff
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 121(9)
Autor:
F, Wisløff, N, Gulbrandsen
Publikováno v:
Acta oncologica (Stockholm, Sweden). 39(7)
The effect of interferon on the health-related quality of life in multiple myeloma was assessed in two trials carried out by the Nordic Myeloma Study (Group (NMSG). In both trials, the EORTC QLQ-C30 questionnaire, supplemented with 11 items relating